secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001213900-25-100847
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharmaceuticals raises $6.0M in registered direct offering for LYMPHIR launch
--------------------------------------------------------------------------------

- Gross proceeds ~$6.0M; net ~$5.5M after placement agent fees and expenses.
- Offering: 3,973,510 shares/pre-funded warrants plus 3,973,510 common warrants at $1.51/share.
- Common warrants exercisable at $1.40/share, 5-year term; pre-funded warrants at $0.0001/share.
- Net proceeds to support commercial launch of LYMPHIR™ and other product candidates.
- H.C. Wainwright acted as placement agent; 7.0% cash fee and 278,146 placement agent warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025100847/0001213900-25-100847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025100847/ea0261909-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-100847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer